Experts discuss relevant and actionable strategies for practice improvement as well as timely clinic
How can molecular profiling guide cancer therapy? Join our experts to learn how to best utilize mole
Did you know that more than 20% of patients with chronic inflammatory demyelinating polyneuropathy (
What are the latest advances shaping chronic lymphocytic leukemia (CLL) treatment today? Discover th
Are you up to date on the latest developments in hormone receptor-positive metastatic breast cancer?
Are you ready to answer the last remaining question in sodium-glucose co-transporter 2 (SGLT2) inhib
Do you really know the optimal biomarker tests for personalizing breast cancer treatment? Are some j
Do you know the symptoms that affect more than 80% of people with Alzheimer's disease in some countr
Are you selecting the right Bruton tyrosine kinase (BTK) inhibitor for your patients with chronic ly
Are you looking for practical advice on using ileal bile acid transporter (IBAT) inhibitors in clini
How much do you know about future treatment options for type 2 diabetes (T2D)? Join Drs Vilsbøll and
Do you know the key features of Alagille syndrome and how therapies that target the bile acid cycle
Do you know how to spot when a patient needs more than lifestyle approaches for weight loss? Credit
What are the clinical and cellular effects of stigma in your patients living with HIV? Credit availa
Listen to the experts as they share the latest findings on HER2-directed therapies in the treatment
Do you know how to reduce cardiovascular (CV) risk in your patients living with obesity? What does t
Do you know all there is to know beyond amyloid and tau in Alzheimer's disease? Credit available f
Did you know that there are more than 65 million individuals worldwide with long COVID? Credit avail
Did you know that in women living with HIV menopause symptoms can result in increased psychological
What strategies can reduce development time and accelerate access to next-generation monoclonal anti
Antibody-drug conjugates are revolutionizing the therapeutic landscape for NSCLC. Are you up to date
